ABCL
Price
$2.37
Change
-$0.05 (-2.07%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
705.92M
68 days until earnings call
CYBN
Price
$8.84
Change
+$0.26 (+3.03%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
178.59M
Interact to see
Advertisement

ABCL vs CYBN

Header iconABCL vs CYBN Comparison
Open Charts ABCL vs CYBNBanner chart's image
AbCellera Biologics
Price$2.37
Change-$0.05 (-2.07%)
Volume$17.49K
Capitalization705.92M
Cybin
Price$8.84
Change+$0.26 (+3.03%)
Volume$16.07K
Capitalization178.59M
ABCL vs CYBN Comparison Chart
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. CYBN commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a StrongBuy and CYBN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ABCL: $2.37 vs. CYBN: $8.82)
Brand notoriety: ABCL and CYBN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 100% vs. CYBN: 156%
Market capitalization -- ABCL: $705.92M vs. CYBN: $178.59M
ABCL [@Biotechnology] is valued at $705.92M. CYBN’s [@Biotechnology] market capitalization is $178.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileCYBN’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • CYBN’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABCL and CYBN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 4 TA indicator(s) are bullish while CYBN’s TA Score has 6 bullish TA indicator(s).

  • ABCL’s TA Score: 4 bullish, 6 bearish.
  • CYBN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CYBN is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а +15.93% price change this week, while CYBN (@Biotechnology) price change was +9.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

ABCL is expected to report earnings on Aug 12, 2025.

CYBN is expected to report earnings on Nov 13, 2024.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($706M) has a higher market cap than CYBN($179M). CYBN YTD gains are higher at: -2.721 vs. ABCL (-17.406). CYBN has higher annual earnings (EBITDA): -134.52M vs. ABCL (-211.2M). ABCL has more cash in the bank: 605M vs. CYBN (136M). CYBN has less debt than ABCL: CYBN (0) vs ABCL (67.8M). ABCL has higher revenues than CYBN: ABCL (23.1M) vs CYBN (0).
ABCLCYBNABCL / CYBN
Capitalization706M179M394%
EBITDA-211.2M-134.52M157%
Gain YTD-17.406-2.721640%
P/E RatioN/AN/A-
Revenue23.1M0-
Total Cash605M136M445%
Total Debt67.8M0-
TECHNICAL ANALYSIS
Technical Analysis
ABCLCYBN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 22 days ago
86%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DNLRX60.46N/A
N/A
BNY Mellon Active MidCap I
BUFMX16.60N/A
N/A
Buffalo Mid Cap Growth
FCDAX34.24N/A
N/A
Fidelity Advisor Stock Selector Sm Cp A
TFOAX73.93N/A
N/A
Touchstone Focused A
HLXCX11.26N/A
N/A
Harding Loevner Emer Mkt ex Chn Instl

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+4.76%
CRSP - ABCL
63%
Loosely correlated
+0.03%
ABSI - ABCL
59%
Loosely correlated
+2.52%
BEAM - ABCL
58%
Loosely correlated
+1.60%
RXRX - ABCL
58%
Loosely correlated
+11.85%
VCYT - ABCL
56%
Loosely correlated
+2.98%
More

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
+3.13%
ATAI - CYBN
45%
Loosely correlated
+5.11%
ABCL - CYBN
38%
Loosely correlated
+4.76%
ABSI - CYBN
38%
Loosely correlated
+2.52%
RXRX - CYBN
35%
Loosely correlated
+11.85%
VTGN - CYBN
33%
Loosely correlated
N/A
More